AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients
February 28, 2023 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
Cancer Advances, Inc. Announces Issuance of New U.S. Patent
February 28, 2023 02:00 ET
|
Cancer Advances Inc
DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, announced that the U.S....
Pancreatic Cancer Treatment Market Exhibits 15.7% CAGR to Hit USD 6.85 Billion by 2029
February 20, 2023 07:04 ET
|
Fortune Business Insights
Pune, India, Feb. 20, 2023 (GLOBE NEWSWIRE) -- The global pancreatic cancer treatment market size was worth USD 2.15 billion in 2021 and is slated to rise from USD 2.48 billion in 2022 to USD 6.85...
Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound
February 10, 2023 07:35 ET
|
Sunshine Biopharma Inc.
MONTREAL, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas...
Outlook on the TIL Therapies Global Market to 2035: by Target Indication, Key Players and Key Geographical Regions
February 01, 2023 06:33 ET
|
Research and Markets
Dublin, Feb. 01, 2023 (GLOBE NEWSWIRE) -- The "Global TIL Therapies Market : Distribution by Target Indication, Key Players and Key Geographical Regions: Industry Trends and Global Forecasts,...
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
January 17, 2023 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Jan. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform
December 07, 2022 07:30 ET
|
HCW Biologics, Inc
Allowed Claims for Novel Immunotherapeutic Compound Constructed with Tissue Factor as Platform for Target Binding Domains Patent for Underlying Intellectual Property for HCW9218 Currently in Clinical...
FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference
November 28, 2022 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Bank of...
Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 22, 2022 16:02 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha...
AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 15, 2022 07:00 ET
|
AIM ImmunoTech Inc.
– Company continues to execute and is well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones – Cash position expected to fund operations through end of 2023 ...